Eli Lilly Stock Plummets 18% Amid Obesity Drug Pipeline Concerns

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-08-09 02:10:02

BTCCSquare news:

Eli Lilly's shares tumbled 18% this week, marking a stark reversal for the pharmaceutical giant. The $500 billion behemoth faces headwinds despite a 300% five-year rally fueled by its blockbuster weight-loss drugs. Second-quarter revenues surged 38% to $15.5 billion, with Mounjaro and Zepbound delivering 68% and 172% growth respectively. Yet investors balked at two critical concerns.

Potential US pharmaceutical tariffs threaten to disrupt cost structures, while disappointing trial data for experimental drug orfoglipron revealed alarming patient dropout rates. The market's reaction underscores how even industry leaders face turbulence when growth narratives encounter regulatory and clinical hurdles.

By:

Log in to Reply

Standard Chartered Partners with Animoca Brands and HKT to Pursue Hong Kong Stablecoin License

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.